Filtering by
![152291-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152291-Thumbnail%20Image.png?versionId=iZ6C6s_k46N_QWqSoBwLWGxd_kBVU7Xv&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153910Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=1303570ccef2b14edc8052719e2b84f62bc0a46c88a1d91d0e3ca7ce5ecb68cd&itok=8AbhFPqq)
![150637-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/150637-Thumbnail%20Image.png?versionId=4G0VjWyaaEwTIo4zTGMl7QM5tlj_GEtv&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T235936Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2a2b47e1515788ec54aadbd484998f09b802ceb633b8eb9d0b5156c69066021b&itok=Z8EOJrOT)
![150711-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/150711-Thumbnail%20Image.png?versionId=UCXDDCK0Pl5uMSVduhodR.73siq6RPPt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153910Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=61de383fbbe70c59b72139483616cafb55a81905d6e753ceea5a396864537afb&itok=Q4QEKJu3)
![137413-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137413-Thumbnail%20Image.png?versionId=Wv27ioPs6mvEZNOX9ZI2JpfsM9Rw79oM&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240618/us-west-2/s3/aws4_request&X-Amz-Date=20240618T174550Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=464ddcc632a830f921fadd0cabb71e072c2ceac7905424cfe50458400da275b0&itok=6E7e336R)
![141463-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-06/141463-Thumbnail%20Image.png?versionId=ENeUABe2Oyxa57Ihl_PyS6yF4grzWvE3&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T154456Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=25e0b8adb35752d781eb5d677152ca29b3318012766c800a6e41c2bfe78fafe6&itok=goj-kO6R)
Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice were injected with GL261-luc2 cells, a cell line sharing characteristics of human glioblastoma multiforme (GBM). The mice were imaged using magnetic resonance (MR) at five separate time points to characterize growth and development of the tumor. After 25 days, the final tumor volumes of the mice varied from 12 mm3 to 62 mm3, even though mice were inoculated from the same tumor cell line under carefully controlled conditions. We generated hypotheses to explore large variances in final tumor size and tested them with our simple reaction-diffusion model in both a 3-dimensional (3D) finite difference method and a 2-dimensional (2D) level set method. The parameters obtained from a best-fit procedure, designed to yield simulated tumors as close as possible to the observed ones, vary by an order of magnitude between the three mice analyzed in detail. These differences may reflect morphological and biological variability in tumor growth, as well as errors in the mathematical model, perhaps from an oversimplification of the tumor dynamics or nonidentifiability of parameters. Our results generate parameters that match other experimental in vitro and in vivo measurements. Additionally, we calculate wave speed, which matches with other rat and human measurements.
![148419-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/148419-Thumbnail%20Image.png?versionId=7usgnCkoomGdLtYevlUDyvKJgxQQvAn3&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240619/us-west-2/s3/aws4_request&X-Amz-Date=20240619T050643Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=12a4f3ed3eea5d17488339cc282bce28bda230cc8926d1927cf2ec727fa3da0a&itok=m01ELV8s)
Currently, autonomous vehicles are being evaluated by how well they interact with humans without evaluating how well humans interact with them. Since people are not going to unanimously switch over to using autonomous vehicles, attention must be given to how well these new vehicles signal intent to human drivers from the driver’s point of view. Ineffective communication will lead to unnecessary discomfort among drivers caused by an underlying uncertainty about what an autonomous vehicle is or isn’t about to do. Recent studies suggest that humans tend to fixate on areas of higher uncertainty so scenarios that have a higher number of vehicle fixations can be reasoned to be more uncertain. We provide a framework for measuring human uncertainty and use the framework to measure the effect of empathetic vs non-empathetic agents. We used a simulated driving environment to create recorded scenarios and manipulate the autonomous vehicle to include either an empathetic or non-empathetic agent. The driving interaction is composed of two vehicles approaching an uncontrolled intersection. These scenarios were played to twelve participants while their gaze was recorded to track what the participants were fixating on. The overall intent was to provide an analytical framework as a tool for evaluating autonomous driving features; and in this case, we choose to evaluate how effective it was for vehicles to have empathetic behaviors included in the autonomous vehicle decision making. A t-test analysis of the gaze indicated that empathy did not in fact reduce uncertainty although additional testing of this hypothesis will be needed due to the small sample size.
![148396-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/148396-Thumbnail%20Image.png?versionId=iRYQkrl7IWsmbf4MHyi_kg_Uu69JmA9J&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240618/us-west-2/s3/aws4_request&X-Amz-Date=20240618T021501Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=f49d8491ca9dab8d4c97e6f7a8039cc8a0c8b5321e9bb4c02540278f5179f711&itok=UMffMZb6)
Over time, tumor treatment resistance inadvertently develops when androgen de-privation therapy (ADT) is applied to metastasized prostate cancer (PCa). To combat tumor resistance, while reducing the harsh side effects of hormone therapy, the clinician may opt to cyclically alternates the patient’s treatment on and off. This method,known as intermittent ADT, is an alternative to continuous ADT that improves the patient’s quality of life while testosterone levels recover between cycles. In this paper,we explore the response of intermittent ADT to metastasized prostate cancer by employing a previously clinical data validated mathematical model to new clinical data from patients undergoing Abiraterone therapy. This cell quota model, a system of ordinary differential equations constructed using Droop’s nutrient limiting theory, assumes the tumor comprises of castration-sensitive (CS) and castration-resistant (CR)cancer sub-populations. The two sub-populations rely on varying levels of intracellular androgen for growth, death and transformation. Due to the complexity of the model,we carry out sensitivity analyses to study the effect of certain parameters on their outputs, and to increase the identifiability of each patient’s unique parameter set. The model’s forecasting results show consistent accuracy for patients with sufficient data,which means the model could give useful information in practice, especially to decide whether an additional round of treatment would be effective.
![131372-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/131372-Thumbnail%20Image.png?versionId=mfK6OCI6y0IF_CI3bMfhiSa8X.bsxB_L&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240619/us-west-2/s3/aws4_request&X-Amz-Date=20240619T085924Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=f083d0625dc7617cec00d3f0b5cc9a79e1e00e1071d419cb240257545dac0c28&itok=JTOY_dMr)
![132368-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/132368-Thumbnail%20Image.png?versionId=i4sDQWT41nSWFSnIYaB4esgCA8NFo1TB&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240619/us-west-2/s3/aws4_request&X-Amz-Date=20240619T022605Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0563eda908b09c5b048722d1d351593660854bc7e71040739830c1e57190e579&itok=2x3-PJLr)
![132117-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/132117-Thumbnail%20Image.png?versionId=oUt4dZFnbx8yuZ3QQWuipwoUxV60w78g&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240619/us-west-2/s3/aws4_request&X-Amz-Date=20240619T085924Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=93ce70f2a434b9423f35991c4a91d6028381cd6eb90aaddeaef49874897436ff&itok=DHr4E3BU)